Each Fellow will be co-mentored by two program faculty (one from MD Anderson and one from Rice), with one faculty member having a supervisory and te other a co-supervisory role. The major research training activities will be carried out at the camput location of the primary mentor.
The program includes a total of 34 faculty mentors from MD Anderson Cancer Center (16) and Rice University (18 mentors).
Department of Bioengineering
Ph.D. Foyt Family Professor and Chair of Department of
The Bao Laboratoryhas been developing genome editing, nanotechnology and biomolecular engineering approaches for basic biological studies and medical applications. Current cancer-related methodology development includesCRISPR/Cas9 based genome editing, magnetic nanoparticle heating, superparamagnetic nanoparticles for invivo imaging and drug delivery, and viral-vector based in vivo gene delivery. Projects available for T32 trainees include the design, validation and optimization of gene-editing machinery for cell based therapies; synthesis,costing and functionalization of magnetic nanoparticles and nanoclusters; cellular and targeted in vivo delivery using nanoparticles; iron oxide nanoparticle based immunosorbent assays for early cancer detection; and magnetic nanoparticle based hyperthermia and free radical generation for cancer immunotherapy. Dr. Bao hastrained 31 PhD students and 31 postdocs over the last 25 years. Currently he supervises 7 PhD students, 2 postdocs and 2 research faculty in his lab.
Biomolecular Engineering and Nanomedicine (Bao Lab)
Diehl, Ph.D. Associate Professor
The Diehl Laboratory is developing new experimental technologies and theoretical models to study functional interrelationships between genes, proteins and other biochemical reactions in cells. They have established an array of experimental tools to define the composition and nanometerscale organization of proteins complexes, both in vitro and in living cells. Their efforts are focused primarily on examining the mechanisms underlying the regulation and dysregulation of intracellular transport and cytoskeletal dynamics in various human diseases, including cancer, immunodeficiency, and neuronal degeneration. Overall,the ability to engineer and modulate the design of these complexes provides new abilities to develop systems level descriptions of their role in cell physiology and human disease.
Macromolecular Systems Bioengineering Group
Drezek, Ph.D. Professor
Full Professor: Dr. Drezek’s laboratory has combined gold nanoshell based photothermal therapy with CpG immunotherapy to promote the immune stimulatory effects of photothermaltherapy (PTT) and to reduce the immune suppressive outcomes following ablation. Immunostimulatory CpGoligodeoxynucleotides trigger toll-like receptor 9 (TLR9) to activate dendritic cells, promote stimulatory cytokinerelease, and reduce the suppressive activity of MDSCs. Dr. Drezek observed that administering CpGimmunotherapy with photothermal therapy improved tumor burden and survival outcomes in a metastaticmelanoma model. Combining PTT and CpG with other therapies that support anti-tumor immunity could furtherimprove outcomes. For example, combining photothermal therapy with CpG immunotherapy and sunitinibchemotherapy will synergistically reduce immune suppressive MSDC levels and stimulate strong, durable, and systemic anti-tumor responses. Dr. Drezek has mentored 25 PhD students, including 5 prior Medical Sciences Training Program students and 2 postdoctoral fellows.
Optical Molecular Imaging and Nanobiotechnology Laboratory
Hilton, Ph.D. Assistant Professor
The Hilton laboratory has four unique cancer-related projects available for MDACC-Rice T32 trainees. First, we are using CRISPR/Cas-based epigenome editing technologies to maphow different chromatin modifications influence the expression of key oncogenes. Second, we are using synthetic transcription factors to tightly control the expression of oncogenes in human cells to uncover new drug targets and evaluate how oncogene expression levels tip the balance from healthy to diseased cellularphenotype(s). Third, we are using multiplexed synthetic transcription factors to engineer transcriptional networks to precisely model oncogenesis and the response of cancer cells to therapeutics. Fourth, we are using CRISPRbasedscreening methods to identify drivers of drug resistance in cancer. These projects provide ample opportunities for MDACC-Rice T32 trainees to actively contribute to the fight against cancer and to become future scientific leaders in understanding and curing cancer.
Lu, Ph.D. Assistant Professor
The Lu group studies and designs gas vesicles (GVs), a class ofgenetically encodable gas-filled protein nanostructures that enable the use of ultrasound to image signaling pathways and control cellular behaviors. GVs were evolved in photosynthetic microbes, which express themintracellularly to float to the surface of water for maximal photosynthesis. Specific project areas for the T32 fellows include (1) the development of multi-color ultrasound imaging of engineered cells in centimeter-deep tissue for cancer research. (2) The use of GVs to study trackable and controllable tumor-homing bacteria by engineering bacteria that can be remotely controlled by focused ultrasound. The Lu lab will engineer endogenous bacterial residents to treat specific types of cancers such as glioblastoma, and the platform technology can be further extended to other types of tumors that have the presence of a rich microbiome.
Gas-Filled Protein Nanosturctures Lab
McHugh, Ph.D. Assistant Professor
The McHugh Lab has two projects that are focused on improving cancer treatment. The first aims to use the unique properties of the lab’s core-shell microparticles to deliver innate immunostimulatory molecules to evoke immune activity in hepatocellular carcinoma. The second project aims to use genome editing tools (i.e., CRISPR/Cas9) to develop a personalized cancer immunotherapy based on the presence of patient-specific cancerous mutations. After identifying a patient’s unique cancer-driving mutations, we are designing formulations consisting of Cas9 variants and guide RNA that only recognize and cut the genome in cancer cells. Once cut, a co-delivered plasmid encoding a cytotoxic protein that induces immunogenic cell death, eliciting an immune response against cancer neoantigens.
Richards-Kortum, Ph.D. Stanley C. Moore Professor of
Dr. Richards-Kortum’s laboratory develops cost-effective optical imaging and spectroscopy tools to reduce the incidence and mortality of cancer and infectious disease through early detection at the point of care. In collaboration with MD Anderson, her lab has developed novel cellular and molecular imaging technologies to recognize signatures of earlyneoplastic disease. At the same time, they have developed optically active, targeted nanoparticles and fluorescent dyes to image directly the molecular hallmarks of cancer. Through clinical trials at MD Anderson, Mount Sinai Medical Center, and Tata Memorial Hospital in Mumbai, India, they have optimized these agents and imaging systems, demonstrating that they can detect precancerous lesions and early cancers in the oral cavity and the esophagus with high sensitivity and specificity. More recently, they initiated development ofmolecular-specific contrast agents and optical micro-fluidic chips for point-of-care detection of infectious disease through collaborations at Baylor College of Medicine and the University of Texas Medical Branch in Galveston.
Optical Spectroscopy and Imaging Laboratory
Segatori, Ph.D. Associate Professor
The Segatori Lab focuses on the development of sense-and-respond devices that detect highly dynamic environments with high sensitivity and dynamic resolution. Such cellular devices would provide a transformative technology for the development of diagnostic strategies for personalized medicine approaches and therapeutic systems for self-adjusted delivery. In particular, the smart delivery systems that self-adjust drug dosage would offers promise for the design of therapeutic modalities with limited induction of toxic side effects. Continuous delivery improves patient survival with fewer unwanted side effects, but it is extremely difficult to achieve and represents a burdensome option not always accessible to patients, pointing to the need for cellular devices that sense unwanted effects and adjust drug release. To address this need, the Segatori Lab builds cellular devices that adjust output production in response to expression signatures of unwanted side effects.
Tabor, Ph.D. Assistant Professor
The goal of his lab is to develop the intellectual and experimental foundations needed to reliably engineer life. The Tabor lab has extensive expertise in engineering new cellular sensors to a wide range of chemical and physical signals and use them in different applications, including cancer. Pathogenic bacteria utilize two-component system (TCS) signaling pathways to detect insults and other stimuli in vivo and activate virulence and antibiotic resistance phenotypes in response. The Tabor lab has ported TCSs into laboratory bacteria and replaced all native gene regulatory elements with well-characterized synthetic versions in order to unsilence these pathways in the laboratory. Dr. Tabor trains pre- or postdoctoral students in the synthetic biology and drug development studies, which could lead to new clinicallyrelevant drugs for dangerous antibiotic-resistant pathogens. In his 11 years at Rice, Dr. Tabor has advised 9 Ph.D. students and 7 postdoctoral researchers. Dr. Tabor currently has 7 PhD students.
Tkaczyk, Ph.D. Associate Professor
Dr. Tkaczyk’s research focuses on two aspects of technology development: (1) integrated optical devices for in vivo imaging at the cellular level and (2) snapshot multidimensional imaging modalities to enable rapid monitoring of time-dependent processes such as signaling. In tandem, these technologies enable multimodal, multiplexed, and dynamic approaches at the cellular level with use of nano-agents. An example of first technology includes ultra-slim, high-performance achromatic objectives that allow multi-contrast imaging. The second line of research, snapshot hyperspectral and spectro-polarimetric systems based or invented with Dr. Tkaczyk’s image mapping technology allow rapid identification and monitoring of time-dependent processes (e.g,. in imaging pancreatic β-cell dynamics).
Modern Optical Instrumentation and Bio-imaging Laboratory
Omid Veiseh, Ph.D. Assistant Professor
The Veiseh Lab has been working on peritoneal cancers such as ovarian, colorectal and pancreatic cancers, which are particularly challenging to address with traditional therapeutic approaches. The Veiseh Lab leverages a combination of synthetic biology, biomaterial design, immunoengineering to developclinically translatable immunotherapeutic approaches for the treatment of peritoneal cancers. Pro-inflammatory cytokines can trigger the expansion and activation of cytotoxic T and natural killer (NK) cells for cancer immunotherapy. However, their delivery by intravenous administration is associated with significant side effects. Thus, effective cytokine immunotherapy requires programmable spatial and temporal kinetics of cytokine delivery with tunable dosages and therapeutic windows to maintain immunostimulatory effect while avoiding the toxicity. By extending the half-life of the therapeutic payloads, preventing systemic toxicity, and paving the way for combination products, the novel platform developed in the Veiseh Lab tackles many unmet key challenges of cancer immunotherapy.
Department of Chemistry
Ball, Ph.D. Professor
Zach Ball’s group focusses on novel metal-based strategies for altering protein function, inhibiting signaling pathways, and/or identifying and validating cancer drug targets. The Ball lab has developed a set of bioconjugation methodologies for preparing protein-drug conjugates, as well as protein conjugates with polymers and nano-objects. One key investigation involves the identification of a novel binding site on the oncoprotein STAT3, using a rhodium-catalyzed approach to target validation. We then developed anaphthalene sulfonamide class of STAT3 inhibitors and demonstrated efficacy in arresting the development of chemotherapy-resistant acute myeloid leukemia (AML) in a mouse model. Current work builds on novel protein chemistry to ensure site-specific, homogeneous bioconjugation protocols for antibody-targeted treatment andpolymer- and hydrogel-based delivery.
The Ball Lab
Gustavsson, Ph.D. Assistant Professor
The interdisciplinary work in our lab is focused on thedevelopment and application of 3D single-molecule tracking and super-resolution imaging throughout mammalian cells. We strive to gain detailed information about cellular nanoscale structure, dynamics, and molecular mechanisms by designing and applying innovative and versatile imaging tools. The goal of our research is to improve our understanding of cellular function and pathogenesis to answer biophysical and biomedical questions related to cancers and other diseases.
Link, Ph.D. Full Professor
The Link lab has been synthesizing gold nanoparticles with unique optical properties for cancer imaging and targeted therapy applications. However, concerns about their safety have stunted their representation in practice. All nanoparticles that enter biological fluids are immediately exposed toproteins, and it has been shown that the identity and conformation of proteins that adsorb to nanoparticles critically influences the nanoparticles’ stability and fate. The long-term goal of the Link lab is to understand protein adsorption and dynamics on nanoparticle surfaces forming a protein corona that affects the biological fate of any nanoparticle. Understanding the physiochemical interactions between proteins and nanoparticles has the potential for the design of nanoparticles with engineered protein coronas to improve efficacy and safety of nanoparticle-based cancer treatments.
Single Particle Plasmonics Lab
Xiao, Ph.D. Associate Professor
The Xiao lab has been working on Ewing sarcoma (ES), which is the second most common pediatric bone cancer with peak incidence during the adolescent and young adult period. Projects in the Xiao lab include designing new therapeutic strategies against bone cancer cells anddevelop bone-targeting precision therapeutic biologics for the treatment of ES. One approach is based on site specific conjugation of bisphosphonates to antibodies to deliver a high concentration of therapeutic antibodies to the bone and activated within the acidic tumor microenvironment for better therapeutic efficacy and reduce adverse side effects associated with systemic delivery. This project will yield a collection of bone-targeting antibodies to enhance therapeutic profile on Ewing sarcoma.
Department of Imaging Physics
James Bankson, Ph.D. Professor
Dr. Bankson leads the Magnetic Resonance Systems Lab at MD Anderson and is Deputy Director of the Small Animal Imaging Facility (SAIF). Dr. Bankson’s lab has developed novel instrumentation and acquisition methods for multi-animal imaging to reduce the cost and logistical burden of preclinical MRI incancer research. His group has also developed new acquisition and reconstructions to improve quantitative assessment of tumor tissue using dynamic contrast-enhanced MRI, and most recently, Dr. Bankson’s lab has focused on metabolic MRI using hyperpolarized imaging substrates. Dr. Bankson has co-authored nine manuscripts exploring the development and use of nanoparticles in cancer imaging and therapy.
Magnetic Resonance Systems Lab Small Animal Imaging Facility
Bouchard, Ph.D. Associate Professor
Dr. Bouchard heads the Photoacoustic Imaging Research Lab and is a leader of the SAIF photoacousic and ultrasound core. In this capacity, Dr. Bouchard has pursued research investigations ranging from tumor perfusion/vascularity imaging, assessment of cardiac function, visualization oftargeted gold nanoparticles in a murine tumor model, assessment and development of photoacoustic thermography, and the development/characterization of novel mechanisms of contrast and nano-scale contrast agents. Dr. Bouchard’s laboratory also pursues development of novel photoacoustic imaging technologies for clinical applications involving cancer detection/therapy monitoring and monitoring of cardiac therapies.
Photoacoustic Imaging Research Lab
Fuentes, Ph.D. Associate Professor
Dr. Fuentes has a strong interdisciplinary background in applied mathematics, engineering, high-performance scientific computing, and mathematical modeling of physics-based phenomena. His research motivation is to obtain a working knowledge of the physics, limitations, and approximations of the mathematical models inherent to imaging acquisitions systems and nanotechnology mediated therapies. Active research projects include mathematical modeling of nanotechnology-mediated therapies to make predictions relevant to clinical outcomes. Indeed, a mathematical model of nanoparticle-mediated thermal therapy has been shown to predict the selective heating observed during the image-guided procedure.
Computational Research Lab
Sokolov, Ph.D. Professor
The research in Dr. Sokolov’s labs focuses on the development of nanotechnology-based platforms for early detection, diagnosis, and treatment of cancer. These studies are based on a fundamental understanding of physico-chemical properties of nanoparticles and interactions between nanomaterials and biological environment such as cells and tissue. This knowledge ultimately leads to basic design principles that allow harnessing of nano-scale material properties for improved imaging and therapy of devastating diseases such as cancer.
Biomedical Optics & NanoDiagnostics (BOND) Lab
Ph.D. Assistant Professor
Dr. Wu is directing an independent research lab that applies quantitative imaging analysis and machine learning algorithms to extract clinically relevant and action able biomarkers from medical imaging to personalize cancer patient management. He has been selected to join NCI Awardee Skills Development Consortium (NASDC) and have taken systematical training to further strengthen leadership capacity and enhance mentoring skills. He is K99/R00 awardee and will share his insights with our T32 trainees regarding development of a successful career development award.
John Hazle, Ph.D. Professor and Chair
Dr. Hazle conducts research on image guided therapy (IGT) and preclinical imaging. The IGT program is largely driven by techniques Dr. Hazle’s team developed for estimating temperature in vivo for both ablative and non-ablative thermal therapies. Several graduate students and post-doctoral fellows in the preclinical imaging program have gone on to academic careers. Dr. Hazle’s goal for theT32 is to continue to leverage the outstanding resources, both physical and intellectual, at MD Anderson for the education of the next generation of young scientists in biomedical imaging research using nanotechnologies.
Magnetic Relaxometry Research Laboratory Small Animal Imaging Facility
S. Cheenu Kappadath, Ph.D. Professor
Dr. Kappadath is a board-certified and licensed medical physicist with specialties in Nuclear Medicine Physics and Instrumentation (ABSNM) and Diagnostic Radiologic Physics (ABR) supporting clinical nuclear medicine and radiology. He is actively involved in a variety of prospective clinical trialsin 90Y-radioembolization and research projects in quantitative NM (SPECT/CT and PET/CT) imaging. Collaborating with numerous clinicians on several industry-funded grants, as Principal Investigator (PI) or Co-PI, he has helped advance the understanding of dosimetry and laid groundwork for dosimetry-based radioembolization research.
R. Layman, Ph.D. Associate Professor
Dr. Layman is a medical physicist with research interests in CT. He has an outstanding record of teaching and mentoring junior colleagues. At MD Anderson, Dr. Layman has directly mentored three fellows in the hybrid Imaging Physics Fellowship where one was awarded the Best in Physics award at the annual meeting for the American Association of Physicists in Medicine. Two of the fellows currently have academic appointments at top-tier medical centers. He leads the quantitative CT topics of the funded R01 project that includes training a graduate student and postdoc. Due to his efforts and success of mentoring graduate students, fellows, and faculty, he was recently appointed to be the Director of Faculty Development for the Department of Imaging Physics.
Anthony Liu, Ph.D. Professor
Dr. Liu is Program Director and faculty mentor for the Imaging Physics Hybrid Residency Program. In this role he has a deep commitment and long standing track record supporting training and mentoring of graduate students, postdocs, and residents at MD Anderson. He has mentored more than 20 graduate students, postdocs, visiting scientists, junior faculty and supervised 15 physics residents over his career. These trainees have gone on to successful careers in science and/or clinical imaging physics, and manyof them are now university faculty. His research has been focused on advanced MRI methods for studying brain function and physiology. Dr. Liu has been closely collaborating with clinicians and scientists in the fields of radiology, psychology, neurosurgery and neuroscience, and serving as a principle investigator or a coinvestigator in research grants.
Ma, Ph.D. Professor
Dr. Ma has been a leader in the field of novel data acquisition strategies and image reconstruction algorithms for phase-sensitive MRI, and applications such as clinically practical whole-body MRI and abbreviated breast MRI. His lab has been active and established a successful track record in developing novel deep learning-based MRI techniques and in optimizing and clinically validating advanced MRI techniques such as diffusion weighted imaging, dynamic contrast enhanced imaging, MR spectroscopy, and chemical saturation transfer imaging. He has a track record of innovation with over 20 US and foreign patents (several of which are implemented by leading MRI vendors and in active use by world-wide customers). This experience will be leveraged to teach patent application process to our T32 fellows. During his career, Dr. Ma have mentored 9 graduate students (including 2 PhD candidates who successfully defended their dissertation in the last 2 years), 4 postdocs, and 4 junior faculty on their research and career development. These trainees have gone on to successful careers in science and clinical imaging physics, including faculty and fellowship positions in premiere institutions such as Mayo Clinic, Stanford, MD Anderson, University of Texas Health Science Center.
Mawlawi, Ph.D. Professor
Dr. Mawlawi is working on development of novel techniques for PET/CT image acquisition, correction and reformation, as well as modeling the distribution of novel radiotracers. He has co-authored over 90 peer reviewed articles and book chapters and is the recipient of several grants from industry and professional societies.
Pan, Ph.D. Professor
Dr. Pan is working on improving the image quality of PET/CT, in particular on mitigation of the impact from respiratory motion. He has extensive experiences in imaging of the coronary artery and tumor motion in CT, and mitigation of mis-registration and respiratory motion artifacts in PET/CT. He designed the first prototype 4D CBCT for image-guided radiotherapy on a Varian Trilogy machine as well as the first prototype 4DPET/CT to improve quantitative accuracy of the lung tumor. He also invented average CT to improve registration of the CT and PET data, which has been incorporated in routine PET/CT imaging at MD Anderson to mitigate the mis-registration artifacts between the CT and PET data. Dr. Pan is also interested in bringing the benchtop research results to the clinic as demonstrated by his efforts in clinical implementation of average CT, 4D-CT, 4DCBCT and cardiac CT.
Stafford, Ph.D. Professor
Dr. Stafford has a primary research and clinical focus on MR-guided interventions and therapies. He has a broad background in medical physics, with specific expertise in imaging physics, including MRI and ultrasound. He has developed, validated, and clinically implemented methods for MR temperature imaging applied to focused ultrasound, interstitial ultrasound, laser, and nanoparticle-mediated thermal therapies on clinical MRI scanners. Dr. Stafford has extensive experience in successfully overseeing projects in MR-guided interventions that have covered everything from inception to clinical implementation. He has also written and implemented numerous IACUC approved small and large animal protocols for investigations of MR-guided interventions as well a sparticipated in the writing and execution of approved IRB protocols. He is also a member of the Medical Physics education program and has mentored graduate engineering and physics students from that program, UT Austin, Rice University, and University of Houston. He has also mentored several postdoctoral fellows. Department of Cancer Systems Imaging
Cancer Systems Imaging
Pratip Bhattacharya, Ph.D. Associate Professor
Dr. Bhattacharya develops MR hyperpolarization techniques and metabolicand molecular imaging probes to enhance the sensitivity of current in vivo MR methods for disease diagnosis, particularly in cancer and cardiovascular diseases. Over the past eight years, his laboratory has worked on the development of different modalities of hyperpolarized NMR like Parahydrogen Induced Polarization (PHIP), Dynamic Nuclear Polarization (DNP), Continuous Flow DNP of water and solidstate DNP processes of silicon particles and developed applications in various types of cancer and cardiovascular diseases. The trainees from his laboratory have gone on to develop scholarship and independent careers in next generations of parahydrogen polarizer and hyperpolarized metabolic imaging probes.
Charles Manning, Ph.D. Professor
Dr. Manning is a chemist with a background in radiochemistry, medicinal chemistry and imaging science. His laboratory has focused on the discovery, translation, and validation of chemical and molecular probes for cancer imaging and therapy. Dr. Manning is the Scientific Director of the Center for Advanced Biomedical Imaging (CABI). His laboratory discovers and translates novel radiopharmaceuticals and chemical probes, with emphasis on positron emission tomography (PET) imaging. The lab is very interested in quantifying cellular metabolism non-invasively, including high-affinity ligands for receptor-based targets and metabolic substrate transporters elevated in cancer cells.
Millward, Ph.D. Assistant Professor
Dr. Millward seeks to combine chemistry, directed evolution, and nanotechnology to develop activity- and metabolism-based probes for visualizing cell death and inflammation using optical, magnetic, and nuclear imaging platforms. His work has demonstrated that peptides can be readily adapted for molecular imaging through both rational design and directed evolution. During the previous training grant period Dr. Millward served as the instructor and course coordinator for the T32 summer course “CancerBiology, Imaging, and Therapeutics” which was designed to provide a foundation in cancer biology for incomingT32 trainees. He has also served as a faculty mentor for the NCI-funded MD Anderson Cancer Prevention Research Training Program R25 training grant (R25CA057730-21) and was awarded the Robert M. Chamberlin Distinguished mentor award in 2016.
Department of Radiation Physics
Hyun Cho, Ph.D. Professor
Dr. Cho has devoted much of his recent research effort to develop cancer diagnostic/therapeutic applications using gold and other metal nanoparticles. Specifically, he has been investigating strategies to deliver tumor-specific radiation and thermal therapy by taking advantages of gold nanoparticle-mediated dose enhancement/radiosensitization and plasmonic heating, respectively, and preclinical molecular imaging in conjunction with x-ray fluorescence computed tomography (XFCT). Dr. Cho’s research program covers a wide spectrum of research topics ranging from traditional medical physics to nanotechnology including: (1) Quantification of gold nanoparticle-mediated radiation dose enhancement using experimental and computational techniques; (2) Modeling of gold nanoparticle-mediated radiation response modulation using cellular-/nano-scale Monte Carlo simulations; (3) Development of abenchtop XFCT device for multimodal molecular imaging; (4) Development of x-ray fluorescence imaging techniques with gold nanoparticles and other metal probes; and (5) Quantification of plasmonic heat generation due to gold nanoparticles and near-infrared light using experimental and computational techniques.
Clinical Program Faculty
Erik N. K. Cressman, Ph.D. Associate Professor
Dr. Cressman is a clinician and scientist who is using minimally invasive image-guided techniques for diagnostic and therapeutic procedures on a daily basis. Therefore, he is well aware of the limitations of existing methods and actively search for ways to improve treatment. His background as a chemist with industrial experience prior to becoming an interventional radiologist provides a unique perspective to see opportunities not otherwise apparent. He established the Image-Guided Chemistry Lab (ICGL) and has built a group with multidisciplinary collaborations in related areas including thermal imaging and stress responses. As a physician scientist working in a medical education setting, he has mentored over 70 trainees ranging from undergraduates and medical students to graduate students and postdocs. A number of these trainees have gone on to win multiple grants, awards and scholarships.
Image-Guided Chemistry Laboratory
E. Court, Ph.D. Associate Professor of Radiation
Dr. Court is leading a research group of around 25 researchers (PhD students, faculty and computational scientists), focusing on the development of tools to support access to radiation therapy in low-resource settings. The specific strength of the group is the application of artificial intelligence to radiotherapy, including quality management processes throughout research and development, ensuring a smooth translation to clinical use at our own clinic and across the world.
Sood, M.D. Professor of Gynecologic Oncology &
Dr. Sood's research focuses on developing new therapies aimed at the tumor microenvironment, understanding the mechanisms of RNA interference and developing new approaches for using non-coding RNAs for therapy (developed a first-in-humansiRNA therapeutic), and finding solutions to overcome the deleterious effects of adrenergic signaling on cancergrowth and progression. Dr. Sood has published numerous peer-reviewed articles, has authored and coauthored several book chapters, and serves on the editorial board for several journals. He was selected as an American Cancer Society Research Professor and an elected fellow of the AAAS.